NASDAQ: COO
Cooper Companies
Health Care · Ophthalmic Goods
52-week range
Stock price
Market cap
At each fiscal year end, then the latest quarter end: closing price × shares outstanding.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.$13.8B
Show tableHide table
| Period | Market cap |
|---|---|
| FY2016, ended Oct 31, 2016 | $8.59B |
| FY2017, ended Oct 31, 2017 | $11.7B |
| FY2018, ended Oct 31, 2018 | $12.7B |
| FY2019, ended Oct 31, 2019 | $14.3B |
| FY2020, ended Oct 31, 2020 | $15.7B |
| FY2021, ended Oct 31, 2021 | $20.6B |
| FY2022, ended Oct 31, 2022 | $13.5B |
| FY2023, ended Oct 31, 2023 | $15.4B |
| FY2024, ended Oct 31, 2024 | $20.9B |
| FY2025, ended Oct 31, 2025 | $13.7B |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $13.8B |
Revenue
By fiscal year, then the trailing 12 months.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.$4.24B
Show tableHide table
| Period | Revenue |
|---|---|
| FY2016, ended Oct 31, 2016 | $1.97B |
| FY2017, ended Oct 31, 2017 | $2.14B |
| FY2018, ended Oct 31, 2018 | $2.53B |
| FY2019, ended Oct 31, 2019 | $2.65B |
| FY2020, ended Oct 31, 2020 | $2.43B |
| FY2021, ended Oct 31, 2021 | $2.92B |
| FY2022, ended Oct 31, 2022 | $3.31B |
| FY2023, ended Oct 31, 2023 | $3.59B |
| FY2024, ended Oct 31, 2024 | $3.90B |
| FY2025, ended Oct 31, 2025 | $4.09B |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $4.24B |
Net income and free cash flow
By fiscal year, then the trailing 12 months. Free cash flow is operating cash flow minus capex.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.Show tableHide table
| Period | Net income | Free cash flow |
|---|---|---|
| FY2016, ended Oct 31, 2016 | $274M | $357M |
| FY2017, ended Oct 31, 2017 | $373M | $466M |
| FY2018, ended Oct 31, 2018 | $140M | $475M |
| FY2019, ended Oct 31, 2019 | $467M | $421M |
| FY2020, ended Oct 31, 2020 | $238M | $176M |
| FY2021, ended Oct 31, 2021 | $2.94B | $524M |
| FY2022, ended Oct 31, 2022 | $386M | $450M |
| FY2023, ended Oct 31, 2023 | $294M | $215M |
| FY2024, ended Oct 31, 2024 | $392M | $288M |
| FY2025, ended Oct 31, 2025 | $375M | $434M |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $570M | $678M |
Cash and cash equivalents
At each fiscal year end, then the latest quarter end.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.$155M
Show tableHide table
| Period | Cash and cash equivalents |
|---|---|
| FY2016, ended Oct 31, 2016 | $101M |
| FY2017, ended Oct 31, 2017 | $88.8M |
| FY2018, ended Oct 31, 2018 | $77.7M |
| FY2019, ended Oct 31, 2019 | $89.0M |
| FY2020, ended Oct 31, 2020 | $116M |
| FY2021, ended Oct 31, 2021 | $95.9M |
| FY2022, ended Oct 31, 2022 | $138M |
| FY2023, ended Oct 31, 2023 | $121M |
| FY2024, ended Oct 31, 2024 | $108M |
| FY2025, ended Oct 31, 2025 | $111M |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $155M |
Total debt
At each fiscal year end, then the latest quarter end. Short- and long-term borrowings, excluding leases.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.$2.54B
Show tableHide table
| Period | Total debt |
|---|---|
| FY2016, ended Oct 31, 2016 | $1.54B |
| FY2017, ended Oct 31, 2017 | $1.17B |
| FY2018, ended Oct 31, 2018 | $2.02B |
| FY2019, ended Oct 31, 2019 | $1.83B |
| FY2020, ended Oct 31, 2020 | $1.79B |
| FY2021, ended Oct 31, 2021 | $1.48B |
| FY2022, ended Oct 31, 2022 | $2.76B |
| FY2023, ended Oct 31, 2023 | $2.57B |
| FY2024, ended Oct 31, 2024 | $2.58B |
| FY2025, ended Oct 31, 2025 | $2.50B |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $2.54B |
Shares outstanding
At each fiscal year end, then the latest quarter end, adjusted for splits. Down 2.6% since 2016.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.190M
Show tableHide table
| Period | Shares outstanding |
|---|---|
| FY2016, ended Oct 31, 2016 | 195M |
| FY2017, ended Oct 31, 2017 | 195M |
| FY2018, ended Oct 31, 2018 | 197M |
| FY2019, ended Oct 31, 2019 | 196M |
| FY2020, ended Oct 31, 2020 | 196M |
| FY2021, ended Oct 31, 2021 | 198M |
| FY2022, ended Oct 31, 2022 | 197M |
| FY2023, ended Oct 31, 2023 | 198M |
| FY2024, ended Oct 31, 2024 | 200M |
| FY2025, ended Oct 31, 2025 | 196M |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | 190M |
Buybacks and new shares
By fiscal year, then the trailing 12 months, in dollars. Below zero: bought back. Above zero: issued to employees, sold or used in acquisitions.Figures shown are for the trailing 12 months to Jul 31, 2026. Hover or tap a column for another year.Net: $578M more bought back than issued
Show tableHide table
| Period | Bought back | Paid to employees |
|---|---|---|
| FY2016, ended Oct 31, 2016 | $0 | $29.9M |
| FY2017, ended Oct 31, 2017 | $55.0M | $37.2M |
| FY2018, ended Oct 31, 2018 | $0 | $43.2M |
| FY2019, ended Oct 31, 2019 | $156M | $35.1M |
| FY2020, ended Oct 31, 2020 | $47.8M | $37.6M |
| FY2021, ended Oct 31, 2021 | $24.8M | $43.8M |
| FY2022, ended Oct 31, 2022 | $78.5M | $54.2M |
| FY2023, ended Oct 31, 2023 | $0 | $62.1M |
| FY2024, ended Oct 31, 2024 | $0 | $75.1M |
| FY2025, ended Oct 31, 2025 | $290M | $70.5M |
| Trailing 12 months to Jul 31, 2026 (through Q3 FY2026) | $644M | $65.8M |
Revenue (TTM)
$4.24B
+4.7% YoY
Net income (TTM)
$570M
+39.8% YoY
Cash
$155M
+23.9% YoY
Total debt
$2.54B
+2.7% YoY
Valuation
At current price- Market Cap
- $11.3B
- P/E
- 19.9×
- Forward P/E
- —. Needs analyst estimates; not available from the current data provider
- Price / Sales
- 2.7×
- Price / Book
- 1.4×
- EV / EBITDA
- 14.8×
Growth
Trailing 12 months- Revenue (TTM)
- $4.24B
- Revenue Growth YoY
- 4.7%
- Revenue CAGR 3Y
- 7.3%
- Revenue CAGR 5Y
- 11.0%
- EPS Growth YoY
- 42.6%
- Net Income Growth YoY
- 39.8%
Profitability
Trailing 12 months- Gross Margin
- 65.9%
- Operating Margin
- 12.8%
- Net Margin
- 13.5%
- FCF Margin
- 16.0%
- Return on Equity
- 6.8%
Earnings
Trailing 12 months- Net Income
- $570M
- EPS (diluted)
- $2.91
- EBITDA
- $928M
- Operating Income
- $544M
Balance Sheet
As of Jul 31, 2026- Cash and cash equivalents
- $155M
- Total Debt
- $2.54B
- Net Debt
- $2.39B
- Total Assets
- $12.7B
- Total Liabilities
- $4.34B
- Shareholders' Equity
- $8.33B
Cash Flow
Trailing 12 months- Operating Cash Flow
- $1.03B
- Capital Expenditure
- $355M
- Free Cash Flow
- $678M
Dividends and risk
Last 12 months- Dividend Yield
- 0.0%
- Dividend / Share
- $0.00
- Beta (5Y)
- 0.82
Every ratio is calculated from the company’s reported figures.
Note
Revenue is roughly flat year over year at $4.24B.
Watch
Operating margin narrowed 5.5 pts in a year, to 12.8%.
Note
Net debt of $2.39B is 2.6× EBITDA.
Strength
Turns 16.0% of revenue into free cash flow.
Written by fixed rules from the reported figures, not by a person or an AI.
Latest report
Pro10-K for the fiscal year ended Oct 31, 2025 · filed Dec 5, 2025
The score and findings for the newest report are part of CoreStock Pro, coming soon. Every earlier report is free.
Score of each annual report
0 to 100 · 60 means nothing notable · tap a column for its details
2024 · 10-K59Nothing notable
10-K for the fiscal year ended Oct 31, 2024
Filed Dec 6, 2024 · Read the filing on EDGAR
- Total sales rose about 8% to roughly $3.9 billion, and operating income jumped 32% to $705.7 million.
- Part of the profit jump reflects the absence of last year's $45 million Cook Medical termination fee at CooperSurgical.
- Management and auditor KPMG found internal controls ineffective because of an IT control weakness in CooperSurgical's U.S. operations; this is new.
- Cooper replaced its old credit agreement with a $2.3 billion revolving facility maturing in 2029, and carries $2.6 billion of debt.
Business momentum
Strong improvement
“$ 705.7 18 % $ 533.1 15 % 32 %”
Outlook
Positive
“We are optimistic about the long-term prospects for the worldwide contact lens and general health care markets, and the resilience of and growth prospects for our businesses and products.”
Financial stress
Low
“As of October 31, 2024, the Company was in compliance with all debt covenants.”
Tone against the previous report
About the same
Red flags
- Serious
Weak internal controls
“concluded that the Company's internal control over financial reporting was not effective as of October 31, 2024 due to a material weakness in information technology (IT) general controls for the U.S. operations within the CooperSurgical segment”
Positives
CooperVision, the largest business, grew sales 8% and operating income 15%
“$ 676.2 26 % $ 587.7 24 % 15 %”
CooperSurgical sales rose 10%, helped by the Cook Medical addition and fertility growth
“office and surgical net sales increased primarily due to the addition of Cook Medical on November 1, 2023.”
Operating cash flow rose to $709.3 million, with $1.2 billion of credit still available
“Operating activities $ 709.3 $ 607.5 $ 692.4”
Concerns
Auditor issued an adverse opinion on internal controls
“issued an adverse opinion on the effectiveness of the Company's internal control over financial reporting as of October 31, 2024”
Tax rate climbed again, taking a larger share of profit
“The effective tax rates for fiscal 2024 and 2023 were 32.6% and 28.7%, respectively.”
Interest costs rose further as borrowing and rates increased
“Interest expense increased during fiscal 2024 compared to the prior year, primarily due to higher interest rates and higher debt balances.”
New risks since the previous report
Unfixed control weakness could affect financial reporting and investor confidence
“our ability to record, process and report financial information accurately, and to prepare financial statements within required time periods, could be adversely affected”
Costly multiyear rollout of new business software systems could disrupt reporting and orders
“Implementing a new ERP system can negatively affect not only financial accounting and reporting processes but also external commercial activities such as order receipt and product delivery.”
Global minimum tax rules could raise the company's tax bill
“includes Pillar Two, a global minimum tax rate of 15% that may adversely affect our provision for income taxes.”
Biggest risks named
- Material weakness in internal controls and new software rollout
- Inflation, recession and currency swings
- Significant debt and exposure to interest rates
- Intense competition and pricing pressure from larger contact lens rivals
- Manufacturing disruption and reliance on sole suppliers
Artificial intelligence in this business: Not mentioned
How the score adds up
| Starting point | 60 | |
| Business momentum | +12 | |
| Outlook | +3 | |
| Tone against the previous report | 0 | |
| Financial stress | 0 | |
| Red flags | −15 | |
| New risks | −1.5 | |
| Score | 59 | |
Written by AI (Claude Opus 5.5) from the report’s text. 13 of 13 quotes were found word for word in the filing; the rest are left out. Not investment advice.
All scored reports
| Period | Report | Filed | Score | Momentum | Red flags |
|---|---|---|---|---|---|
| 10-K | Dec 5, 2025 | Pro | |||
| 10-K | Dec 6, 2024 | 59 | Strong improvement | 1 serious | |
| 10-K | Dec 8, 2023 | 65 | Improving | 1 medium | |
| 10-K | Dec 9, 2022 | 61 | Improving | 1 minor | |
| 10-K | Dec 10, 2021 | 70 | Strong improvement | None | |
| 10-K | Dec 11, 2020 | 39 | Sharp deterioration | None | |
| 10-K | Dec 20, 2019 | 75 | Strong improvement | None | |
| 10-K | Dec 21, 2018 | 43 | Sharp deterioration | 1 medium1 minor | |
| 10-K | Dec 22, 2017 | 70 | Strong improvement | 1 medium1 minor | |
| 10-K | Dec 22, 2016 | 70 | Strong improvement | None |
How these scores work
An AI model reads the management discussion, risk factors and legal sections of each report and records what they say, quoting the filing word for word. Fixed rules then turn those findings into a score from 0 to 100, where 60 means nothing notable either way. A score describes the report, not whether the stock is a good investment, and the AI may know how things turned out later, which can colour older scores. Read the methodology
From the 10-Q for Q3 FY2026 (period ended Jul 31, 2026), filed Sep 9, 2026. View filings on SEC EDGAR